Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant atezolizumab plus nab-paclitaxel and carboplatin in high-risk triple-negative breast cancer
2014-005017-23Phase 3Completed
- Sponsor
- Michelangelo Foundation
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by Michelangelo Foundation. Started Oct 2015; status: completed.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2014-005017-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005017-23.